Ards management: Advancements, personalization, outcomes.

Naomi Cohen*

Department of Pulmonary and Critical Care, Hebrew University, Israel

Introduction

Managing Acute Respiratory Distress Syndrome (ARDS) involves a multifaceted approach, continuously evolving with new research and clinical insights. A fundamental aspect centers on mechanical ventilation, which requires careful implementation to optimize patient outcomes. This article brings you up to speed on the latest in mechanical ventilation for ARDS. It covers critical strategies like lung-protective ventilation, finding the right personalized PEEP, managing driving pressure, and how adjunctive therapies fit into modern ventilatory approaches[1].

Understanding the potential for ventilator-induced lung injury (VILI) is also paramount. This article gives you the essential update on how mechanical ventilation can harm lungs and how we prevent it. It reinforces why protective ventilation, with low tidal volumes and optimized PEEP, is absolutely foundational in ARDS care[5].

Another critical component of ARDS management is fluid balance. Here's the thing about fluid management in ARDS: it's a delicate balance. This piece highlights conservative strategies, aiming to cut down on pulmonary edema and boost patient outcomes without sacrificing vital perfusion[2].

Beyond ventilation and fluid management, specific interventions significantly improve patient prognosis. You'll find a clear breakdown of the evidence for prone positioning in ARDS here. It highlights how turning patients face down can really improve oxygenation, lung mechanics, and ultimately, survival, along with practical tips for implementation[4].

For cases of severe ARDS, advanced life support is often necessary. This review gives you a solid update on Extracorporeal Membrane Oxygenation (ECMO)'s place in severe ARDS. It dives into who benefits most, the technical aspects, potential complications, and the latest evidence supporting ECMO as a crucial rescue option[3]. Moreover, other non-invasive strategies are also gaining traction. This review focuses on high-flow nasal cannula (HFNC) for acute respiratory failure, including its place in managing ARDS. It unpacks the physiological advantages and clinical results, giving you a clear picture of its utility[9].

Pharmacological strategies are also a significant area of ongoing research and clinical application. Let's break down the drug options for ARDS. This piece covers both existing and developing pharmacological treatments, like corticosteroids and neuromuscular blockers, weighing their evidence and potential roles in patient management[6]. The quest for more targeted and effective treatments is further supported by the use of biomarkers. This look at biomarkers in ARDS shows how these indicators can help with early diagnosis, predicting outcomes, categorizing patient types, and guiding more personalized treatment approaches[7].

The future of ARDS care increasingly points towards tailored interventions. Thinking about personalized care in ARDS, this article explores how we can identify different patient types and use biomarkers to customize ventilation and drug therapies. The goal, naturally, is to get better results for each individual patient[10]. What this really means is that surviving ARDS isn't the end of the journey. This meta-analysis details the lasting physical, mental, and cognitive challenges survivors face, underscoring why post-Intensive Care Unit (ICU) care and rehabilitation are so vital for improving their quality of life[8]. The collective insights from these articles shape a holistic understanding of ARDS, from acute management to long-term recovery, highlighting both established practices and innovative frontiers in critical care.

Conclusion

This data provides a comprehensive overview of current and emerging strategies in managing Acute Respiratory Distress Syndrome (ARDS). It details crucial advancements in mechanical ventilation, emphasizing lung-protective approaches, personalized positive end-expiratory pressure (PEEP) settings, and managing driving pressure to prevent ventilator-induced lung injury. A significant focus is placed on conservative fluid management to reduce pulmonary edema and improve patient outcomes while maintaining vital perfusion.

Beyond foundational care, the review delves into advanced supportive therapies. Prone positioning is highlighted for its effectiveness in improving oxygenation and lung mechanics, ultimately boost-

***Correspondence to:** Naomi Cohen, Department of Pulmonary and Critical Care, Hebrew University, Israel. E-mail: naomi.cohen@hebrew-univ.edu

Received: 01-Jul-2025, Manuscript No. AAJPCR-25-214; **Editor assigned:** 03-Jul-2025, Pre QC No. AAJPCR-25-214 *(PQ)*; **Reviewed:** 23-Jul-2025, QC No. AAJPCR-25-214; **Revised:** 01-Aug-2025, Manuscript No. AAJPCR-25-214 *(R)*; **Published:** 12-Aug-2025, DOI: 10.35841/aajpcr-8.4.214

Citation: Cohen N. Ards management: Advancements, personalization, outcomes. J Pulmonol Clin Res. 2025;08(04):214.

ing survival. Extracorporeal Membrane Oxygenation (ECMO) is presented as a critical rescue option for severe ARDS, with discussions on patient selection, technical aspects, and potential complications. High-flow nasal cannula (HFNC) also finds its place, offering physiological advantages for acute respiratory failure, including in ARDS.

Pharmacological interventions, encompassing existing and developing drug options like corticosteroids and neuromuscular blockers, are evaluated for their evidence and role in patient care. The data also explores the promising area of biomarkers, showing their potential for early diagnosis, outcome prediction, patient phenotyping, and guiding more personalized treatment. In this vein, personalized medicine in ARDS aims to tailor ventilation and drug therapies based on individual patient characteristics. Crucially, the long-term impact on ARDS survivors is addressed, revealing persistent physical, mental, and cognitive challenges and underscoring the importance of post-Intensive Care Unit (ICU) rehabilitation to improve quality of life.

References

1. Marc S, T P, Jean-Michel A. Mechanical ventilation in ARDS: what is new?. *Intensive Care Med.* 2021;47:737-751.
2. Giacomo B, John G L, *T P. Conservative fluid management in acute respiratory distress syndrome. Intensive Care Med.* 2020;46:2-15.
3. Karthik R, Kiran S, *Roanna R L. Extracorporeal membrane oxygenation* (ECMO) in acute respiratory distress syndrome (ARDS): a comprehensive review of recent advances. Crit Care. 2021;25:101.
4. Giacomo G, Carolina P, Jean-Michel A. The evidence behind prone positioning in acute respiratory distress syndrome: a review. *Curr Opin Crit Care.* 2023;29:1-8.
5. Edward C G, Ewan F, Arthur S S. Update on ventilator-induced lung injury and protective ventilation. *N Engl J Med.* 2020;383:2261-2274.
6. Michael A M, B T T, *Lorraine B W. Pharmacologic Management of Acute Respiratory Distress Syndrome. Crit Care Med.* 2020;48:153-162.
7. Francisco G, Carolina P, Jean-Michel *A. Biomarkers in Acute Respiratory Distress Syndrome. J Clin Med.* 2022;11:4214.
8. Sandra O, Veerle V P, Daniel D B. Long-term outcomes in survivors of ARDS: a systematic review and meta-analysis. *Intensive Care Med.* 2023;49:858-868.
9. Bram R, Shai E, Daren C. High-flow nasal cannula in acute respiratory failure: a narrative review. *Intensive Care Med.* 2020;46:953-965.
10. Claude G, T P, *V Marco R. Personalized medicine in ARDS. Intensive Care Med.* 2023;49:379-391.

Citation: *Cohen N. Ards management: Advancements, personalization, outcomes. J Pulmonol Clin Res. 2025;08(04):214.*